Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
midazolam; CP-690,550+ midazolam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | - |
| Treatment Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| midazolam; CP-690,550 + midazolam | DRUG | Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID |
| CP-690,550 + midazolam; midazolam | DRUG | Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone |
Inclusion Criteria: * Healthy male and/or female (non-child bearing potential) subjects Exclusion Criteria: * Clinically significant infections within the past 3 months * History of previously untreated infection with Mycobacterium tuberculosis * Positive screening test for hepatitis B surface an...
Midazolam is a small molecule drug studied by Pfizer in a Phase 1 drug-drug interaction trial. The trial combined midazolam with CP-690,550 in healthy adult volunteers. The specific therapeutic indication for this combination study is not publicly disclosed.
Pfizer, Inc. (ticker: PFE) is the developer associated with the midazolam and CP-690,550 drug-drug interaction study. The trial was conducted in the United States and enrolled 25 healthy volunteers.
Midazolam, in the context of the CP-690,550 combination study, is in Phase 1 clinical development. The single listed trial, NCT00902460, has been completed. It was a controlled, randomized Phase 1 study with 25 enrolled participants.
Midazolam was evaluated in one completed Phase 1 trial, NCT00902460, titled CP-690,550 and Midazolam Drug-Drug Interaction Study. The trial enrolled 25 healthy volunteers in the United States, was randomized and controlled, and did not use double blinding.